These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 11762712)
1. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Jiménez RG; Moreno AS; Gonzalez EN; Simón FJL ; Rodriguez JR; Jimenez JC; Córdoba MH; Albertino RV; Jimenez RA Thyroid; 2001 Nov; 11(11):1031-4. PubMed ID: 11762712 [TBL] [Abstract][Full Text] [Related]
2. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Daumerie C; Vynckier S; Caussin J; Jadoul M; Squifflet JP; de Patoul N; Wambersie A Thyroid; 1996 Aug; 6(4):301-4. PubMed ID: 8875750 [TBL] [Abstract][Full Text] [Related]
3. 131I treatment of thyroid papillary carcinoma in a patient with renal failure. Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192 [TBL] [Abstract][Full Text] [Related]
4. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure. Modarresifar H; Almodovar S; Bass WB; Ojha B Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187 [TBL] [Abstract][Full Text] [Related]
5. Iodine 131 ablation therapy for a patient on maintenance haemodialysis. Howard N; Glasser M Br J Radiol; 1981 Mar; 54(639):259. PubMed ID: 7470791 [No Abstract] [Full Text] [Related]
6. [Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure]. Andres A; Tardín L; Santapau A; Razola P; Prats E; Parra A; Rivas MA; Ruiz P; Alvarez R; Camara A; Banzo J Rev Esp Med Nucl; 2010; 29(1):32-5. PubMed ID: 20018412 [TBL] [Abstract][Full Text] [Related]
7. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease. Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699 [TBL] [Abstract][Full Text] [Related]
8. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model. Pahlka RB; Sonnad JR Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898 [TBL] [Abstract][Full Text] [Related]
9. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Mello AM; Isaacs R; Petersen J; Kronenberger S; McDougall IR Clin Nucl Med; 1994 Sep; 19(9):776-81. PubMed ID: 7982310 [TBL] [Abstract][Full Text] [Related]
11. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786 [TBL] [Abstract][Full Text] [Related]
12. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications. Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635 [TBL] [Abstract][Full Text] [Related]
13. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868 [TBL] [Abstract][Full Text] [Related]
14. The management of well-differentiated thyroid cancer with end-stage renal disease. Wang TH; Lee CH; Tseng LM; Liu RH Endocrine; 2003 Aug; 21(3):227-31. PubMed ID: 14515006 [TBL] [Abstract][Full Text] [Related]
15. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure. Yeyin N; Cavdar I; Uslu L; Abuqbeitah M; Demir M Nucl Med Commun; 2016 Mar; 37(3):283-7. PubMed ID: 26619394 [TBL] [Abstract][Full Text] [Related]
16. Radioactive 131I use in end-stage renal disease: nightmare or nuisance? Sinsakul M; Ali A Semin Dial; 2004; 17(1):53-6. PubMed ID: 14717812 [TBL] [Abstract][Full Text] [Related]
17. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257 [TBL] [Abstract][Full Text] [Related]
18. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma. Fofi C; Festuccia F; Barberi S; Apponi F; Chiacchiararelli L; Scopinaro F; Punzo G; Menè P Int J Artif Organs; 2013 Jun; 36(6):439-43. PubMed ID: 23653300 [TBL] [Abstract][Full Text] [Related]
19. Use of radioactive iodine I-131 and monitoring of radioactivity in patients with chronic kidney disease on haemodialysis. Gallegos-Villalobos A; García-López F; Escalada C; Ortiz JJ; Cardona J; Medina A; Portolés J Nefrologia; 2014 May; 34(3):317-22. PubMed ID: 24798564 [TBL] [Abstract][Full Text] [Related]
20. [Necessity to administer 131I in a patient with papillary thyroid carcinoma undergoing chronic hemodialysis]. Novik V; González R; Díaz M; Vega J Rev Med Chil; 1998 Jul; 126(7):874-5. PubMed ID: 9830782 [No Abstract] [Full Text] [Related] [Next] [New Search]